Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study Comparing Pharmacokinetics, Safety, Tolerability And Immunogenicity Of FKB327 A Biosimilar Of Adalimumab With European Union (EU)-Approved Humira And United States (US)- Licensed Humira After Single Subcutaneous Doses In Healthy Subjects.

Next Previous
Trial Profile

A Study Comparing Pharmacokinetics, Safety, Tolerability And Immunogenicity Of FKB327 A Biosimilar Of Adalimumab With European Union (EU)-Approved Humira And United States (US)- Licensed Humira After Single Subcutaneous Doses In Healthy Subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; First in man; Pharmacokinetics

Most Recent Events

  • 08 Feb 2017 New trial record
  • 30 Jan 2017 Primary endpoint (Equivalence analysis of the geometric means of AUC0-t , AUC0-infinity and Cmax for FKB327, EU-Humira and US-Humira, and that EU-Humira and US-Humira) has been met, according results to published in the British Journal of Clinical Pharmacology.
  • 30 Jan 2017 Results published in the British Journal of Clinical Pharmacology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top